# Efimosfermin alfa PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/efimosfermin-alfa

> The next catalyst for efimosfermin alfa, sponsored by GSK plc (GSK), is its topline data readout, Mar to Jun 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | efimosfermin alfa |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Metabolic Dysfunction-associated Steatohepatitis](https://sec-api.dev/indications/metabolic-dysfunction-associated-steatohepatitis), [Non-alcoholic Fatty Liver Disease](https://sec-api.dev/indications/non-alcoholic-fatty-liver-disease), [Liver Diseases, Alcoholic](https://sec-api.dev/indications/liver-diseases-alcoholic) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221188 (A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07221188

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221227 (A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07221227

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221188 (A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07221188

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221227 (A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07221227

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Liver Diseases, Alcoholic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07791043 (A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07791043

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Liver Diseases, Alcoholic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07791043 (A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07791043

### Oct 2030 to Jan 2031: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Metabolic Dysfunction-associated Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07704892 (A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07704892

### October 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Metabolic Dysfunction-associated Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07704892 (A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07704892

## Same indication

- [Efinopegdutide](https://sec-api.dev/pdufa/efinopegdutide) (MRK)
- [GSK4532990](https://sec-api.dev/pdufa/gsk4532990) (GSK)

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03), [August 2028](https://sec-api.dev/fda-calendar/2028-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/efimosfermin-alfa.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Efimosfermin alfa PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/efimosfermin-alfa

```bibtex
@misc{secapidev_pdufa_efimosfermin_alfa_20261116,
  title        = {Efimosfermin alfa PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/efimosfermin-alfa}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_efimosfermin_alfa_20261116","title":"Efimosfermin alfa PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/efimosfermin-alfa","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
